GNRH1 and ovarian hyperstimulation syndrome: In the case of the trigger to induce ovulation (which was indicated once a follicle reached 20 mm), the most frequently used drug was human chorionic gonadotropin (Choriomon®, IBSA) (45%), followed by recombinant hCG (Ovidrel®, Merck Pharmaceuticals) (35%), and gonadotropin-releasing hormone (GnRH) agonist (Gonapeptyl Daily®, Ferring) (hyper-responders or patients suspected for ovarian hyperstimulation syndrome) in doses of 0.2 mg (20%).